Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Neena M. Patil Sells 3,800 Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Jazz Pharmaceuticals Stock Down 2.3 %

Shares of JAZZ opened at $140.22 on Tuesday. The firm has a market cap of $8.52 billion, a P/E ratio of 19.75, a PEG ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06. The stock’s 50 day moving average is $127.01 and its two-hundred day moving average is $119.37. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC lifted its holdings in Jazz Pharmaceuticals by 238.6% during the third quarter. Private Advisor Group LLC now owns 7,716 shares of the specialty pharmaceutical company’s stock valued at $860,000 after purchasing an additional 5,437 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Jazz Pharmaceuticals by 15.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,476 shares of the specialty pharmaceutical company’s stock worth $275,000 after purchasing an additional 325 shares during the last quarter. Stephens Inc. AR lifted its stake in Jazz Pharmaceuticals by 16.1% in the 3rd quarter. Stephens Inc. AR now owns 5,563 shares of the specialty pharmaceutical company’s stock valued at $620,000 after buying an additional 771 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Jazz Pharmaceuticals by 11.4% in the 3rd quarter. Van ECK Associates Corp now owns 60,211 shares of the specialty pharmaceutical company’s stock worth $6,691,000 after buying an additional 6,157 shares during the last quarter. Finally, AlphaCentric Advisors LLC increased its stake in Jazz Pharmaceuticals by 40.9% during the 3rd quarter. AlphaCentric Advisors LLC now owns 15,500 shares of the specialty pharmaceutical company’s stock worth $1,727,000 after buying an additional 4,500 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on JAZZ. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. Finally, Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $182.47.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.